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Summary The aim of this study was to analyse the clinical significance of Cathepsin D (Cath D) content as determined by an
immunoradiometric assay in a series of primary untreated ovarian cancers from 162 patients. In addition, immunohistochemical analysis of
Cath D was also performed on a subset of 86 tumours. Cath D levels were distributed in an asymmetrical way and were skewed towards the
lower values (median value 20.8 pmol mg-' protein, range 2.0-99.0 pmol mg-' protein). No correlation was found between Cath D levels and
clinicopathoiogical parameters. However, the percentage of Cath D positivity was significantly higher in oestrogen receptor-positive (57%/6)
compared with oestrogen receptor-negative (36%) cases (P= 0.01). The percentage of Cath D-positive staining was not significantty different
for both epithelial (27%) and stromal components (400/o). Immunoradiometrically detected Cath D levels were not different according to Cath
D stromal immunostaining (P= 0.18), while higher Cath D levels were measured in Cath D-positive than in Cath D-negative tumour epithelial
cells (P = 0.027). Survival analysis was conducted on 161 primary untreated ovarian cancer patients. The 5-year overall survival rate was
57%/o and 55% in Cath D-positive and Cath D-negative patients respectively (P = 0.69). As far as time to progression was concemed, there
was no significant difference in the survival rate of patients with eiter high or low Cath D content (P = 0.56). Similar results have been
obtained in the subset of patients in which Cath D was analysed by immunohistochemistry. In conclusion, Cath D measuremnent in tumour
extracts appears to have a limited usefulness in improving the prognostic characterization of ovarian cancer patients.
Keywords: Cathepsin D; ovarian cancer prognosis
Proteolytic enzymes. which are involved in basement membrane
and extracellular matrix degradation. may affect tumour invasive-
ness and metastatic potential (Liotta et al. 1995). Among the
different classes of proteases. particular attention has focused on
cathepsins, a family of enzymes that include cystein-proteases.
such as Cathepsin B (Cath B). and aspartyl-proteases. such as
Cathepsin D (Cath D).
Cath D. first identified as a 52-kDa oestrogen-regulated glyco-
protein (Westley et al, 1979). displayed both proteolytic and
autocrine mitogenic activity in breast cancer cells in vitro (Vignon
et al. 1986). The involvement of Cath D in cancer invasion has
also been supported by the demonstration that transfection of
tumorigenic rat cells with Cath D cDNA increases their metastatic
potential in animal models (Garcia et al, 1990).
The possible clinical significance ofCath D expression was first
investigated in breast cancer patients in whom high Cath D levels
were reported to be associated with metastatic lymph node
involvement, high risk of relapse and poor prognosis (Spyratos et
al, 1989; Isola et al. 1993: Gion et al. 1995).
Regarding ovarian cancer. there is some in vitro evidence that
oestrogen-stimulated ovarian tumour cells are able to secrete Cath
D into the culture medium (Galtier-Dereure et al. 1992), suggesting
that cathepsins may play a role in ovarian cancer cell biology. In
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addition, it has been reported that Cath D is able to activate the
precursor form of Cath B (Van der Stappen et al. 1996) and that
higherCath B activity is associated with an increased percentage of
relapses in ovarian cancer patients (Kozyreva et al. 1994).
In addition. higher Cath D concentrations have been found in
cytosolic extracts from omental metastases than from primary
ovarian tumours. as reported by us and other authors (Scambia
et al, 1991: Henzen-Logmans et al. 1994). Moreover. the possible
association of Cath D with ovarian cancer patient prognosis has
been only preliminarily investigated (Scambia et al. 1994).
The aim of this study was to analyse the clinical significance of
Cath D content detennined by an immunoradiometric assay in a
large series ofprimary untreated ovarian tumours from 162 patients.
The correlation between Cath D and biological parameters. such as
oestrogen receptor (ER). progesterone receptor (PR) and epidermal
growth factorreceptor (EGFR). were also investigated.
In addition. the specific contribution of tumour epithelial and
adjacent stromal cells to total Cath D content was studied by
immunohistochemistry on a subset of 86 cases. and the possible
relationship between immunohistochemical and immunoradio-
metric results was also analysed.
MATERIALS AND METHODS
One hundred and sixty-two previously untreated patients with
histologically confirmed diagnosis of ovarian carcinoma were
admitted to the study. Seventy-two cases were from our previous
study (Scambia et al. 1994). None of the patients had received
chemotherapy previously. All patients were staged according to
the FIGO (International Federation ofGynecology and Obstetrics.
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Table 1 Distributon of Cathepsin D levels according to dinicopahological characteristcs in ovarian cancer
Cathepsin D (pmxl mg-' cytosolic protein)
Variable No. Mean Median Standard Range P-value
deviatonm
All cases 162 25.8 20.8 18.4 2.0-99.0
Histotype
Serous 112 24.2 17.1 17.9 2.0-99.0
Mucinous 8 22.8 18.8 11.4 11.4-41.9
Endometnoid 20 19.9 19.1 11.4 3.9-35.6 NS
Undifferentiated 13 28.2 30.3 11.3 14.5-46.0
Other 9 22.9 22.9 21.3 8.0-54.4
Grading
1-2 39 24.4 20.2 14.7 4.6-72.9 NS
3 108 25.1 18.0 19.0 2.0-99.0
Not available 15 34.6 28.8 21.4 4.4-84.4
FIGO stage
H-l4 29 20.9 15.7 11.9 4.4-54.4
III 112 24.9 19.8 17.2 2.0-85.0 0.026
IV 21 37.4 27.5 26.8 6.1-99.0
Ascites
No 69 23.3 21.5 12.3 2.0-64.0 NS
Yes 93 27.3 18.0 21.7 3.9-99
Residual tumour-
<2ccm 96 25.2 20.8 17.8 2.0-99.0 NS
> 2 cm 43 28.6 20.6 22.3 4.2-99.0
Response to chemotherapya
Complete 57 25.6 20.2 18.3 5.6-99.0
Partial 39 23.2 19.8 14.9 2.0-54.2 NS
No Change/progression 34 31.2 25.0 24.4 3.9-99.0
aOnly stage 1IV cases.
1987) classification and histological1v classified according, to the
World Health Organization (WHO) (Serov et al. 1979). In some
cases (n = 15.) it was impossible to obtain the information relative
to histopatholooical grading from the pathology reports.
All patients unders ent maximal cytoreductive effort. and
analvses relatixe to residual tumour were all performed consid-
erinc only stage II-IV patients (n = 139). Only stage II-IV patients
underwent chemotherapy. which was instituted 2-3 weeks after
surgery. Gynaecological examination. abdominopelvic ultrasonog-
raphy. CA 125 assay and radiological investigation. if necessary.
were performed monthl for the clinical assessment of response.
which was recorded according to WHO criteria (World Health
Organization. 1979.) Approximately 28 days after the last
course. clinically complete responders underwent second-look
laparoscopy. In laparoscopy-negative cases. second-look laparo-
tomry was performed for the assessment of pathological response.
In nine patients. a second-look laparotomy was not performed
because ofpatient refusal for a second surgenr. During laparotomy.
after peritoneal washing and a careful inspection of the abdominal
cavity. a biopsy ofall suspicious lesions was performed and. in the
case of no evidence of disease. at least 20 random biopsies were
taken. Patients who initially had only an explorative laparotomy
underwent a second laparotomv after chemotherapv. and a second
cvtoreduction was attempted.
Tumour tissue processing
At the time of surgery. the tumour specimens were dissected and
divided into txo parts: one part %vas frozen in liquid nitrogen and
stored at - 80CC to be used forreceptor detection and the other part
was fixed for 24 h in neutral-buffered formalin. After fixation.
blocks were routinely paraffin embedded.
Preparation of cytosol and membrane fractions
Briefly. tumour specimens were finely minced and homogenized
in five volumes of ice-cold buffer [25 mm Tris. 1.5 mms EDTA.
5 mm sodium azide. 0.1%7 monothioglvcerol and 20%7 glycerol
(TENMG). pH = 7.4] by applying several intermittent bursts
of an Ultra-Turrax homogenizer. The crude homogenate Aas
centrifuged at 7000g for 20 min at 0 C. The supernatants were
then centrifuged at 105 000g for 75 min at 0C. obtaining the
cvtosolic fraction and the membrane pellet (Scambia et al. 19951.
Immunoradiometric assay
Cath D concentration was assayed in the cvtosolic fraction
using a solid-phase two-site immunoradiometric assay (CIS
Bioindustries. Gift-Sur-Yvette. France). Protein concentration was
measured by the Bradford method (Bradford. 1976). using bovine
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Table 2 Distributon of Cathepsin D positvity according to cJinicopathological characteristics in ovarian cancer
Cathepsin D posifivity
Tumour P-value Tumour-adjacent P-value
epithelial cells stromal cells
Variable No. No.(%) No.(%)
All cases 86 23 (27) 35 (40)
Hystotype
Serous 61 15 (25) 22 (37)
Mucinous 4 1 (25) NS 2 (50) NS
Endometnoid 10 2 (22) 5 (55)
Undifferentiated 8 3 (42) 2 (28)
Other 3 -
Grading
1-2 20 3 (15) NS 6 (30) NS
3 58 18 (30) 26 (44)
Not available 8 -
FIGO stage
Il 18 6 (33) 9 (44)
III 54 13 (24) NS 21 (39) NS
IV 14 4 (28) 6 (43)
Ascites
No 35 9 (26) NS 16 (46) NS
Yes 51 14 (27) 19 (37)
Residual tumoura
s 2 cm 54 15 (28) NS 23 (43) NS
>2cm 17 2(12) 8(47)
Response to chemotherapya
Complete 29 7 (24) 8 (27)
Partial 19 5 (25) NS 11 (58) 0.07
No Change/progression 19 4 (21) 10 (53)
aOnly stage IH-V cases.
serum albumin as standard. and w as reset to approximateIl
1 mg ml-' before Cath D assav. C tosols were then diluted 1:40
and 1:80 with the diluent contained in the kit. Radioactivity was
measured in a y-counter for 1 min. Intra- and interassavvariations
were 5.8% and 8.9% respectixelv.
Receptor assay
ER and PR were measured using the dextran-coated charcoal
(DCC) assay according to the European Organization for the
Research and Treatment of Cancer (EORTC) protocol (EORTC
Breast Cancer Cooperative Group. 1980). EGFR was assayed as
previously described (Scambia et al. 1995). Values of 5. 10 and
1.5 fmol mg-' ofprotein were used to define. respectively. ER. PR
and EGFR positixity.
Immunohistochemical assay
Immunohistochemical stainincg was performed on formalin-fixed.
paraffin-embedded sections from a subset of 86 oxarian cancer
patients whose characteristics did not differ from those described
in the total population.
The avidin-biotin-peroxidase complex method (ABC) (Hsu et
al. 1981) (DAKO. Carpinteria. CA. USA) and the specific poly-
clonal antihuman cathepsin D antibody (Dako. Carpinteria. USA)
were used for immunohistochemistry. The specificity of the
immunostainingx was controlled w-ith a preadsorption experiment
in which anti-Cath polyclonal antibody was preincubated with a
100-fold molar excess ofpurified Cathepsin D. Immunostaining of
tumour cells as well as macrophages was abolished.
Fixe-micrometre sections were dewaxed in xylene. rehydrated
in descending concentration of alcohol dow n to 80%7. washed in
tap and distilled water. and treated with 0.3% hydrogen peroxide in
methanol for 25 min to remove endogenous peroxidase actix-itx.
The sections were then washed in Tris-buffered saline (TBS)
(pH 7.6) and incubated with normal serum as the blocking reagent
to minimize non-specific binding. A 1:200 dilution of the specific
polvclonal rabbit anti-human Cath D antibody was applied for
30 mm at room temperature. The sections were then incubated
with the biotinylated goat anti-rabbit IgG and with avidin-
biotin-peroxidase complex for 10 min at room temperature.
Finallv. the sections were washed in TBS. stained by incubation
with diaminobenzidine for 10 min and then counterstained with
haematoxylin. Normal rabbit immunoglobulin G (IgG: Sigma. St
Louis. MO. USA) was used as a negatixe control.
Cath D immunostaining evaluation
Separate exaluation of neoplastic and stromal (i.e. fibroblasts and
mononuclear cells) elements was performed by means of light-
microscopic examination.
The sections were examined independently by two obserxers
(AC and AF) and scored according to the intensity ofstaining and
proportion of cells stained. In case of disagreement. the sections
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according to immunohistochemical Cathepsin D status
Cathepsin D (pmol mf1 cytosolic protein)
Tumour cells No. Median Range P-value
EpithilS
Positive 23 32.8 10.7-72.6 0.027
Negative 63 20.8 3.9-99.0
Stromal
Positive 35 22.9 3.9-99.0 0.18
Negative 51 24.7 4.4-99.0 1 1 1 III I I
0 10 20 30 40 50 60 70 80 90 100
Cathepsin D(pmol mg1 cytosolic protein)
Figure 1 Distributon of Cath D levels in 162 primary ovarian tumours. The
class interval is 10 pmol mg-' protein
were reviewed on a two-headed microscope (Laborlux-S. Leitz) to
reach a consensus. In detail, the cases were scored as negative
when no staining was observed. When reactivity was observed in
less than 25% of tumour cells or in few stromal cells, the cases
were scored 1+. When the positivity was observed in 25-75% of
tumour cells or in a moderate number of stromal cells, the cases
were scored 2+. When > 75% of tumour cells or many stromal
cells were positive. the cases were scored 3+.
In this study. cases with scores between - and 1+ were consid-
ered as negative. while cases with scores between 2+ and 3+ were
considered as Cath D positive. The interpretation of the immuno-
staining was determined without any knowledge of the clinico-
pathological and biochemical parameters or ofthe follow-up data.
Statistical analysis
Kruskal-Wallis and Mann-Whitney non-parametric tests were
used to analyse the distribution of cytosolic Cath D content
according to clinicopathological characteristics of the patients.
Mann-Whitney non-parametric tests was used to analyse the
distribution ofER. PR and EGFR. according to Cath D status. The
Fisher exact test for proportion was used to analyse the distribu-
tion of Cath D-positive cases in epithelial and in stromal cells in
relation to clinicopathological characteristics and receptor status.
All medians and life-tables were calculated using the product-limit
estimate, and the curves were examined by means of the log-rank
test (Mantel, 1966). Cox's analysis was used to evaluate the prog-
nostic significance of Cath D as a continuous variable. Time to
progression and overall survival were calculated from the day of
the first surgery to the date of clinical or pathological progression
or death. All survival analyses were performed using Solo
Statistical Software (BMDP Statistical Software. Los Angeles.
CA. USA).
RESULTS
Immunoradiometric analysis
The distribution of Cath D levels in 162 primary ovarian tumours.
including previously described tumours (Scambia et al. 1994). is
shown in Figure 1. Cath D levels were distributed in an asym-
metrical way and were skewed towards the lower values (median
value 20.8 pmol mg-' protein. range 2.0-99.0 pmol mg-' protein).
The association between Cath D levels and recognized prog-
nostic factors is shown in Table 1. No correlation was found with
grading. histology, presence of ascites and residual tumour. In
addition, the lack ofassociation between Cath D and these clinico-
pathological characteristics was confirmed by referring to Cath D
positivity as defined by using different cut-off values.
Cath D levels were significantly higher in stage III (median
19.8. range 2.0-85.0 pmol mg-' cytosolic protein) and stage IV
(median 27.5. range 6.1-99.0 pmol mg-' cytosolic protein)
patients compared with stage I-IH (median 15.7. range 4.4-
54.4 pmol mg-' cytosolic protein) cases (P = 0.026).
We did not observe any correlation between Cath D values and
response to chemotherapy. as reported in Table 1.
The association between Cath D content and steroid hormone
and EGF receptors measured in the cytosolic fraction was also
investigated: the percentage ofCath D positivity was significantly
higher in ER-positive (57%) than in ER-negative (36%) cases
(P = 0.01). Also. when PR and EGFR levels were assayed. no
correlation was found to exist with Cath D levels.
Immunohistochemical analysis
Figure 2 shows a representative example of a Cath D immuno-
histochemical staining in a primary ovarian cancer. A specific
cytoplasmic staining was observed in epithelial as well as in
stromal cells. Cath D-positive stromal cells were mainly repre-
sented by reactive fibrohistiocytic cells and macrophages that
were concentrated immediately adjacent to tumour cells.
The percentage of Cath D-positive epithelium was 27% (23 out
of 86 patients), and this was calculated not to be significantly
different with respect to the percentage of Cath D positivity in
stromal cells (35 out of 86 patients) (40%). In addition. there was
no association between Cath D epithelial and Cath D stromal
staining (data not shown).
When Cath D staining in the epithelium was evaluated
according to clinicopathological parameters. no relationship
appeared to exist between the presence or absence of Cath D
staining and any clinical parameters (Table 2). However, patients
whose tumours showed positively stained stroma demonstrated a
trend towards partial or no response to chemotherapy (P = 0.07).
Steroid hormone receptor and EGFR levels were not differently
distributed according to Cath D status in epithelial and stromal
cells (data not shown).
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Figure 2 Immunohistochenical staining of Cath D in primary human ovarian cancer (ABC method). (A and C) Positive reaction for Cath D is seen
predoninantly in eptheal tmour cells (origina magxniicaton A, x400; C x100). (B and D) Positive reacbon for Cath D is seen predominantly in intratumoral
histocytes and fbroblsts (onginal magnification B, x400; D, x100)
Relationship between immunoradiomeric and
immunohistochemical assay
A relationship was observed between Cath D levels measured by
immunoradiometry and epithelial Cath D content detected by
immunohistochemistry (P = 0.027), while this relationship did not
exist for stromal cells (P = 0.18) (Table 3).
Survival analysis
Survival analysis was conducted on 161 primary untreated ovarian
cancer patients. One patient died from intercurrent disease. During
follow-up, death and progression of disease was observed in 55
and 85 patients respectively.
Different cut-off values, corresponding to the upper. the lower
quartiles and the median Cath D levels were tested to distinguish
low vs high Cath D content groups.
Figure 3A shows the overall survival curves in relation to Cath
D cytosolic status, defined using a cut-offof21 pmol mg-' protein.
corresponding to the median value. The 5-year overall survival
was 57% and 55% in Cath D-positive and Cath D-negative
patients respectively (P = 0.69). Similar results were obtained at
any cut-offtested (data not shown).
As far as time to progression is concemed, no significant differ-
ence in the survival rate of patients with high or low Cath D
content was observed. as shown in Figure 3B (P = 0.56). Cox's
Hazard regression analysing Cath D as a continuous variable gave
similar results (data not shown).
Survival analysis was also conducted on the subgroup of 86
patients in whom Cath D was analysed by immunohistochemistry.
The 5-year time-to-progression rate was 23% for epithelial Cath
D-positive compared with 38% for epithelial Cath D-negative
cases (P = 0.91) and 30% for stromal Cath D-positive compared
with 37% forstromal Cath D-negative cases (P =0.67). The 5-year
overall survival was not significantly different between Cath D-
positive and Cath D-negative cases for both epithelial (P = 0.94)
and stromal (P = 0.67) components.
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Figure 3 Overall survival (A) and time-to-progression (B) according to cytosolic Cath D status in primary ovarian cancer patients
DISCUSSION
To our knowledge. this is the first study to investigate the possible
clinical role of Cath D content in a large series of primary
untreated ovarian cancer patients by means of both immunoradio-
metric and immunohistochemical assays.
The present study, which also includes previously analysed
cases (Scambia et al. 1994), was conceived to clarify the possible
association between Cath D and ovarian cancer patient clinical
outcome. as our preliminary findings only demonstrated a border-
line and a not easily explainable association between cytosolic
Cath D levels and prognosis in ovarian cancer.
In the present report. which refers to a larger sample population
observed for a longer follow-up period. the potential clinical
significance ofCath D expression has been analysed using several
Cath D cut-off points and. more importantly. by using Cath D as a
continuous variable. The latter approach has the advantage of
retaining all the information of the biological markers and
excludes the bias due to preselection of the best discriminating
cut-off points (Altman et al. 1992). Data reported here suggest that
the assessment of total cytosolic Cath D levels in tumour extracts
has limited usefulness in improving the prognostic characteriza-
tion of ovarian cancer patients, thus emphasizing the need to be
careful when reporting the prognostic value of a new biological
factor based on a pilot study. Large. multi-institutional, confirma-
tory (phase Ill) studies have been recommended to reach reliable
conclusions about the possible clinical usefulness of biological
factors as new prognostic indicators in human malignancies
(Simon et al. 1994).
Our results have been obtained by means of a biochemical
assay. measuring Cath D levels in total cvtosolic fractions from
tumour samples. Therefore. it is possible that the tumour samples
contain invading stromal and inflammatory cell contaminants.
which have been reported to express high levels of Cath D (Imort
et al. 1983). possibly leading to an inappropriate estimation of the
role ofthis protease.
Only scanty data have been reported until now on the immuno-
histochemical evaluation of Cath D content in ovarian cancer
(Athanassiadou et al. 1997) and the relative contribution ofepithe-
lial and stromal cells to total Cath D expression levels. Also the
correlation between cytosolic Cath D levels of a tumour and
specific Cath D immunostaining have not been analysed.
In order to investigate whether epithelial and stromal Cath D
content can be independently associated to ovarian cancer patient
clinical outcome. we analysed Cath D expression by means of
immunohistochemistry on a subset of pnrmary ovarian tumours
that had also been evaluated for their cytosolic Cath D content.
We demonstrated that, in our series. cytosolic Cath D levels
were directly associated with immunohistochemically detected
Cath D content for the epithelial tumour cells. as reported by
several authors for breast cancer (Eng Tan et al. 1994: Roger et al.
1994). On the other hand, this association has not been found for
stromal cells. thus indicating that epithelial cell Cath D content
mainly contributes to total Cath D in tumour extracts.
Overall, using both methods of determining Cath D content in
ovanan tumours, no correlation was found to exist between Cath D
levels and patient outcome.
Ourdata are different to those reported forbreast cancer patients
in whom. in spite of some discrepancies. there has been general
agreement to consider high Cath D expression as being a marker
of unfavourable clinical outcome (Ferrandina et al. 1997).
Patterns of ovarian cancer spread are rather peculiar as ovarian
tumour cells thrive in the abdominal cavity microenvironment and
can easily reach distant sites on peritoneal surfaces. Moreover. the
biological and clinical role of lymphatic dissemination in ovarian
cancer natural history is yet to be fully clarified. In this context. the
different clinical significance of Cath D expression in breast and
ovarian tumours could be a result of the different biological roles
that the protease system might play in these two neoplasias. It is
conceivable that the degradative enzyme machinery may not be as
relevant for ovarian cancercells as forbreast cancer cells. in which
the degradation of basement membrane and extracellular matrix
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by means ofproteolytic enzymes represents a key step during local
metastatic process. Further studies are needed to gain a deeper
insight into the molecular patterns regulating key steps in ovarian
tumour cell invasiveness and spread.
In addition, it is possible that regulation of the net protease
activity balance, involving cathepsin proenzymes, inhibitors and
the urokinase-type plasminogen activator system (uPA), which
interact with each other, is different in ovarian than in breast
cancer cells.
Rochefort et al (1987) reported that Cath D secretion can be
induced by oestradiol in human breast cancer cells. Tamoxifen has
also been demonstrated to induce, through its oestrogenic activity,
an increase in Cath D mRNA levels in breast cancer cells in vitro
(Johnson et al, 1989; Chalbos et al, 1993) and in vivo
(Maudelonde et al, 1994). In our series, higher Cath D levels were
found in ER-positive tumours, in accordance with results by
Galtier-Dereure et al (1992), who demonstrted that secretion of
pro-Cath D in BG-1 ovarian tumour cells is oestrogen responsive.
However, considering Cath D as a markerofoestrogen responsive-
ness is debatable, as even the role ofoestrogen receptors in ovarian
tumours is still controversial.
In conclusion, Cath D assessment seems to have little meaning, if
any, in characterizing ovarian cancer patient prognosis. However, it
has to be taken into account that Cath D might act as a trigger of
potentially important proteolytic cascades, thus leading to the activa-
tion ofproenzyrnes, such as Cath B and uPA, the latter having been
recently reported to be associated with an unfavourable prognosis in
ovarian cancerpatients (Kozyreva etal, 1994; Kuhn et al, 1994).
Therefore, the simultaneous assessment of a panel of function-
ally related proteases and their inhibitors could be helpful in clari-
fying the biological and possibly the clinical role of these factors
in ovarian cancer.
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